HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/19/2012 -- Arena Pharmaceuti (NasdaqNM:ARNA) reported EPS of -0.606. For the Current Fiscal year, the company is expected to report EPS of -0.25. For the Next Quarter and Next Year, the company is expected to report EPS of 0.12 and -0.15 respectively. At Current Market Price, ARNA is in distance of +11.80% from its 50-ARNAday Moving Average price of $8.2823 and +45.05% from its 200-day Moving Average price of $6.3838. Arena Pharmaceuticals (NAS: ARNA) added another 7% to yesterday's 3% gain, despite the news that rival obesity drug Qsymia by Vivus was commercially available. Having a competitor beat you to market is generally a bad thing, but this was widely expected, since Arena's Belviq is tied up in the DEA classification process. Besides, Belviq will be on the market soon enough, and the winner won't be decided in the first few months. Arena's rise this week is probably just momentum behind both obesity-drug makers, but at these lofty levels, a stumble by either one on launch could dampen enthusiasm for the space.
Should Investor Buy Or Sell ARNA Now : Click Here
Celsion Corporati (NCM:CLSN) is +0.36 - +7.00% from the previous close of $5.14. It traded between $5.10 - 5.78 with total traded volume of 2226706 shares. Keep a close eye on CLSN, as the stock has been showing unusual moves over the past weeks. At Current market price, CLSN has recovered +237.42% from its 52-week Low of 1.63 and has Pulled back -4.84% from its 52-week high of 5.78.Celsion Corporation (Nasdaq: CLSN), high of $5.78. Celsion said its HEAT Study was given FDA Fast Track Designation and has been designated as a Priority Trial for liver cancer by the National Institutes of Health. Celsion continues to face a compelling market opportunity, especially in the area of liver cancer, which is increasingly prevalent throughout Asia. Even if this company dilutes current shareholders with a 40% expansion in the share count, then you're still looking at a $300 million market value, which is well below the ultimate potential market size for the company's ThermoDox technology.
Should Investor Buy Or Sell CLSN Now : Click Here
Neuralstem, Inc. (AMEX:CUR) reported EPS of -0.209. For the Current Fiscal year, the company is expected to report EPS of -0.20. For the Next Quarter and Next Year, the company is expected to report EPS of -0.05 and -0.21 respectively. At Current Market Price, CUR is in distance of +85.47% from its 50-day Moving Average price of $0.7549 and +50.05% from its 200-day Moving Average price of $0.933. Neuralstem, Inc.(NYSEAMEX:CUR) shares climbed 13.91% and closed at $1.31 in the last trading session. The company announced the pricing of a registered direct offering of 7 million shares of its common stock, offered at a price to the public of $1.00 per share. The gross proceeds to Neuralstem from this offering are expected to be $7.0 million. The offering is expected to close on or about September 19, 2012. Aegis Capital Corp. is acting as sole placement agent for this offering.
Can CUR Extend Gain? Find Out Here
Sarepta Therapeut (NGM:SRPT) reported EPS of -0.678. For the Current Fiscal year, the company is expected to report EPS of -1.04. For the Next Quarter and Next Year, the company is expected to report EPS of -0.30 and -1.40 respectively. At Current Market Price, SRPT is in distance of +38.47% from its 50-day Moving Average price of $11.454 and +128.31% from its 200-day Moving Average price of $6.9468. Sarepta Therapeutics, Inc. (SRPT) had a flag or consolidation pattern, it bounced, and then moved up slowly. On Tuesday, it tested lateral price resistance at the prior high around 16.25. It backed off and closed up 1.01 to 15.86, or 6.8%, on 3.4 million shares. Look for this stock to make it to 20 on a swing trade.
Should Investor Buy Or Sell SRPT Now : Click Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)